Chaetoglobosin K inhibits tumor angiogenesis through downregulation of vascular epithelial growth factor-binding hypoxia-inducible factor 1α

Anti-Cancer Drugs

Volumn 24, Issue 7, 2013, Pages 715-724

  Luo, Haitao ^a   Li, Bingyun ^b,c   Li, Zhaoliang ^a   Cutler, Stephen J ^e   Rankin, Gary O ^d   Chen, Yi C ^a  

^a Alderson Broaddus College   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Akt; angiogenesis; chaetoglobosin K; hypoxia inducible factor; ovarian cancer cells; vascular epithelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; FUNGAL EXTRACT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; PROTEIN KINASE B; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ASSAY; FEMALE; FUNGUS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CHICK EMBRYO; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDOLE ALKALOIDS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879977648     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283627a0b     Document Type: Article

References (26)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-236.
2. Mai PL, Wentzensen N, Greene MH. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res 2011; 4:303-306.
3. Cramer DW, Bast RCJ, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res 2011; 4:365-374.
4. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res 2011; 4:375-383.
5. Banks E. The epidemiology of ovarian cancer. In: Bartlett JMS, editor. Ovarian cancer methods and protocols. New York: Humana Press Inc. 2000. pp. 3-11.
6. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. A combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117-1130.
7. Fishman DA, Schwartz PE. Current approaches to diagnosis and treatment of ovarian germ cell malignancies. Curr Opin Obstet Gynecol 1994; 6:98-104.
8. Wingo PA, Cardinez CJ, Landis SH, Greenlee RT, Ries LA. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer 2003; 97:3133-3275.
9. Bertl E, Bartsch H, Gerhäuser C. Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol Cancer Ther 2006; 5:575-585.
10. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9:2-10.
11. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
12. Sánchez-Muñoz A, Pérez-Ruiz E, Mendiola Fernández C, Alba Conejo E, González-Martín A. Current status of anti-angiogenic agents in the treatment of ovarian carcinoma. Clin Transl Oncol 2009; 11:589-595.
13. Cutler HG, Crumley FG, Cox RH, Cole RJ, Dorner JW, Chaetoglobosin K. A new plant growth inhibitor and toxin from diplodia macrospora. J Agric Food Chem 1980; 28:139-142.
14. Springer JP, Cox RH, Cutler HG, Crumley FG. The structure of chaetoglobosin K. Tetrahedron Lett 1980; 21:1905-1908.
15. Tikoo A, Cutler HG, Lo SH, Chen LB, Maruta H. Treatment of ras-induced cancers by the F-actin cappers tensin and chaetoglobosin K, in combination with the caspase-1 inhibitor N1445. Cancer J Sci Am 1999; 5:293-300.
16. Maruta H, He H, Tikoo A, Nur-E-Kamal M. Cytoskeletal tumor suppressors that block oncogenic ras signaling. Ann N Y Acad Sci 1999; 886:48-57.
17. Matesic DF, Blommel ML, Sunman JA, Cutler SJ, Cutler HG. Prevention of organochlorine-induced inhibition of gap junctional communication by chaetoglobosin K in astrocytes. Cell Biol Toxicol 2001; 17:395-408.
18. Sidorova TS, Matesic DF. Protective effect of the natural product, chaetoglobosin K, on lindane-and dieldrin-induced changes in astroglia: identification of activated signaling pathways. Pharm Res 2007; 25:1297-1308.
19. Matesic DF, Villio KN, Folse SL, Garcia EL, Cutler SJ, Cutler HG. Inhibition of cytokinesis and Akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells. Cancer Chemother Pharmacol 2006; 57:741-754.
20. Ali A, Sidorova TS, Matesic DF. Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells. Invest New Drugs 2012. doi: 10.1007/s10637-012-9883-x.
21. Luo H, Rankin GO, Liu L, Daddysman MK, Jiang BH, Chen YC. Kaempferol inhibits angiogenesis and VEGF secretion through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer 2009; 61:554-563.
22. Luo H, Rankin GO, Juliano N, Jiang BH, Chen YC. Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFkB-cMyc-p21 pathway. Food Chem 2012; 130:321-328.
23. Jiang Y, Cukic B, Adjeroh DA, Skinner HD, Lin J, Shen QJ, et al. An algorithm for identifying novel targets of transcription factor families: application to hypoxia-inducible factor 1 targets. Cancer Inform 2009; 7:75-89.
24. Leung KW, Ng HM, Tang MK, Wong CC, Wong RN, Wong AS. Ginsenoside-Rg1 mediates a hypoxia-independent upregulation of hypoxia-inducible factor-1a to promote angiogenesis. Angiogenesis 2011; 14:515-522.
25. Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, et al. Involvement of Akt and mTOR in chemotherapeutic-and hormonalbased drug resistance and response to radiation in breast cancer cells. Cell Cycle 2011; 10:3003-3015.
26. Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, Cullinane C, et al. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. Mol Cancer Ther 2011; 10:1440-1449.